GSK: 3 Key Takeaways for Long-Term Investors

Source The Motley Fool

Key Points

  • GSK started 18 phase 3 clinical trials in 2026.

  • Specialty medicine sales grew 15% in the third quarter.

  • Year-to-date cash generation reached GBP 7.4 billion.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, GSK (NYSE:GSK) reconfirmed its full-year 2026 guidance as sales grew 5% to GBP 8.9 billion. This commercial trajectory shows how effectively the drugmaker transitions from legacy primary-care treatments toward high-margin specialty therapies. Three things management said stand out.

1. Pipeline Acceleration Expands Late-Stage Clinical Trials

The drugmaker is accelerating its research and development (R&D) pipeline to generate long-term organic growth. It has initiated 18 phase 3 clinical trials in 2026 and expects to reach 22 by the end of the year.

Across R&D, we continue to make fantastic progress in accelerating our late-stage pipeline. ... We've now started 18 phase III studies, with a further four on track to start before the end of the year.
-- Tony Wood, Pipeline Update

2. Specialty Medicines Drive Revenue Growth and Market Share

Specialty medicines, including long-acting human immunodeficiency virus (HIV) treatments, grew 15% in the third quarter. These higher-margin therapies offset broader price pressures across the inhaler market.

Commercial momentum continued in the Q3, driven mainly by specialty medicines, up 15%. ... Cabenuva remains the only long-acting injectable regimen for HIV treatment, establishing a strong foundation with patients who prefer to take medicines less frequently.
-- Nina Mojas, Growth Drivers

3. Restructuring Program Reallocates Capital to Core Assets

Management launched the Accelerate Growth program to streamline support operations and supply chain logistics. The program redirects savings toward late-stage drug development while maintaining operating profit margins.

Operating profit grew 5%, with the margin broadly stable, as increased R&D investment was broadly offset by cost of goods and SG&A productivity as we further match our cost base to the evolving portfolio.
-- Julie Brown, Financial Performance

Looking Ahead

Operating momentum in specialty launches positions the business well for full-year performance. Structural advantages in long-acting HIV regimens and expanded oncology indications provide lasting pricing power, while management tracks pricing discipline across respiratory lines.

Looking ahead, we remain on track to deliver our full year 2026 guidance. Sales are expected in the upper half of the range, driven by specialty performance.
-- Julie Brown, Financial Performance

Long-term value creation relies on executing this accelerated development program while maintaining strict cost control.

To close, we remain focused on executing our strategy, which is built on driving top-line growth, building and accelerating the late-stage portfolio, and actively reallocating resources to where they can create the largest value for patients and shareholders.
-- Luke Miels, Chief Executive Officer

Should you buy stock in GSK right now?

Before you buy stock in GSK, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GSK wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia reports tomorrow with an interim CEO — $108 billion is the easy numberNvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
Author  Irene Q.
Yesterday 02: 11
Nvidia closed at 162.85 on Friday, down 12.75% on the week and 32% below its 6 October record, with market value down to $3.92 trillion. The Q3 bar is $108 billion ±2%, and consensus already sits at $108.7 ~ 108.8 billion, so the revenue line is not where the surprise lives. The number that decides the reaction is the 71 ~ 72% Q4 gross-margin trough, followed by a Q4 guide against a $124.9 billion consensus. This piece prices the print, marks the 158.39 line and lays out the three scenarios in a table.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
Yesterday 02: 27
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Weekly Report: The index rose 2.5% while Nvidia fell 12.7% — two equity divergences, one should closeThe S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
Author  Irene Q.
Yesterday 02: 35
The S&P 500 rose 2.51% to 7,561.67 and the QQQ rose 3.63% to 679.89 last week, while Nvidia fell 12.75% to 162.85 — a sixth straight weekly loss and 32% below its October record. In the same five sessions, energy equities rose 5.42% while WTI fell 2.52%. Both pairs normally move together (60-day correlations of +0.64 and +0.58). This report ranks which divergence closes first, with the trigger for each.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
Yesterday 02: 45
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
placeholder
Weekly Report: DXY 103.41, 10-year 5.15%, AUD carry 3bp — three FX regimes flipped in one weekThe dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
Author  Irene Q.
Yesterday 03: 26
The dollar index rose 1.09% to 103.41, a 19-month high, while the US 10-year closed at 5.154% and the Australia-US two-year spread collapsed to about 3 basis points from 36. EURUSD fell 1.59% to 1.1024, USDJPY rose 1.51% to 159.78 and AUDUSD fell 1.79% to 0.6764, a 10-month low. Three FX regimes — the broad dollar, the US rate level and the Australian carry premium — flipped in the same week. This report marks the thresholds, ranks which one can flip back first, and lists the week's calendar.
goTop
quote